SANDOZ LESCOL (FLUVASTATIN) IS FIRST "ENTIRELY SYNTHETIC" HMG- CoA
SANDOZ LESCOL (FLUVASTATIN) IS FIRST "ENTIRELY SYNTHETIC" HMG- CoA reductase inhibitor and "is in part structurally distinct from the fungal derivatives of this therapeutic class," labeling states. Lescol was approved as a cholesterol-lowering agent on Dec. 31 ("The Pink Sheet" Jan. 3, p. 18). It will be the fourth HMG-CoA reductase inhibitor on the market, after Merck's Mevacor (lovastatin) and Zocor (simvastatin) and Bristol-Myers Squibb's Pravachol (pravastatin).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth